Fri, Feb 26th, 2021
Subscribe
Log In
Lists
Book of Lists
The Money Issue
LA500
Wealthiest Angelenos
Health Care
Real Estate
Finance
Manufacturing
Tech
Infrastructure
Travel/Leisure
Media
Professional Services
Events
2021 Events
2020 Events
2019 Events
Custom Features
Custom Content
Trusted Advisors
People on the Move
Companies on the Move
Videos
×
Los Angeles Business Journal
Orange County Business Journal
San Diego Business Journal
San Fernando Valley Business Journal
Subscribe
Follow
Follow our NEWS
Facebook
Twitter
Instagram
LinkedIn
Follow our EVENTS
Facebook
Twitter
Instagram
Email Alerts
Log In
Search
×
Friday, February 26, 2021
Fri, Feb 26th, 2021
Subscribe
Log In
Lists
Book of Lists
The Money Issue
LA500
Wealthiest Angelenos
Health Care
Real Estate
Finance
Manufacturing
Tech
Infrastructure
Travel/Leisure
Media
Professional Services
Events
2021 Events
2020 Events
2019 Events
Custom Features
Custom Content
Trusted Advisors
People on the Move
Companies on the Move
Videos
Home
Belldegrun, Arie — Allogene Therapeutics Inc
Executive Chairman and Co-Founder
Allogene Therapeutics Inc.
THE LATEST: Pharma entrepreneur and cell therapy pioneer Belldegrun made headlines in March when he was diagnosed with Covid-19 and went into self-quarantine at his home, showing only mild symptoms. In January Allogene Therapeutics, the gene therapy cancer treatment company Belldegrun launched in 2017, entered into a collaboration with SpringWorks Therapeutics of Stamford, Conn., to evaluate SpringWorks' drug to treat a rare form of multiple myeloma cancer.
BACKGROUND: Belldegrun, a physician who still teaches urology at UCLA, previously founded cancer biopharmaceutical company Kite Pharma, which was acquired by Gilead Sciences Inc. in 2017 for about $12 billion. He has founded or helped build a number of biopharma companies, including Cougar Biotechnology Inc. and Agensys Inc. He also is chairman of Two River Group Holdings, UroGen Pharma Ltd. and Kronos Bio Inc. and serves as a senior managing director of Vida Ventures, a life-sciences investment firm he co-founded.
YEARS ON THE LA500: 5
Return to the 2020 edition of the LA500.